相关实验视频

Updated: Jan 12, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

坚持辅助内分泌疗法,包括GnRH类似物和存活率:基于人口的队列研究

Louise Eriksson Bergman^1,2, Alexios Matikas^1,3, Xingrong Liu¹

¹Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

EClinicalMedicine

|November 3, 2025

概括

辅助性内分泌疗法将GnRH类似物与他莫西芬或AI结合在一起,在绝经前乳腺癌患者中显示较低的坚持. 不坚持这些治疗与侵袭性乳腺癌无生存率较差有关.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
流行病学流行病学

背景情况:

辅助性内分泌疗法 (AET) 结合性腺激素释放激素类似物 (GnRHa) 与他莫西芬 (TAM) 或芳香酶抑制剂 (AI) 改善了患有乳腺癌的绝经前妇女的生存率.
这种组合治疗越来越多地被处方,但对患者的坚持存在担忧.

研究的目的:

评估早期乳腺癌前更年期妇女不同辅助内分泌治疗方案的坚持率.
评估AET的坚持与无侵袭性乳腺癌生存率 (IBCFS) 之间的关联.

主要方法:

基于人口的队列研究,使用瑞典国家医疗保健登记册 (2007-2020年) 对16468名患有早期ER阳性乳腺癌的妇女进行了研究.
AET分为AI,TAM,GnRHa + TAM和GnRHa + AI. 这三种类型的AET可以分为AI,TAM,GnRHa + TAM和GnRHa + AI. 坚持被定义为药物持有率≥80%或事件最短的间隔.
后勤回归和Cox比例危险模型用于分析不合规性及其与IBCFS的关联.

主要成果:

对AI的坚持率为86%,对TAM的79%,对TAM+GNRHa的75%,对AI+GNRHa的75%.
与单独使用人工智能相比,对TAM (OR1.40),TAM + GnRHa (OR2.73) 和AI + GnRHa (OR2.92) 观察到更高的非坚持率.
不遵守与显著较差的IBCFS相关 (HR 1.43在1年,HR 1.19在5年).

结论:

在绝经前乳腺癌患者中,组合疗法 (GnRHa + TAM或AI) 的辅助内分泌疗法的坚持率低于单剂药物.
不遵守AET显着与侵袭性乳腺癌无生存率的减少有关.
需要进一步的前性研究来证实这些发现,并探索改善遵守的策略.

关键词:

坚持的坚持坚持的坚持一个辅助的辅助.乳腺癌乳腺癌乳腺癌合规性合规性合规性内分泌疗法是一种内分泌疗法.释放性腺激素的类似物,释放性腺激素的类似物.预测预后预测预测幸存的生存方式

更多相关视频

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...